Eurocine Vaccines AB Stock

Equities

EUCI

SE0015382155

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
0.055 SEK 0.00% Intraday chart for Eurocine Vaccines AB -15.38% +19.57%
Sales 2022 0.07 0.76 Sales 2023 0 0.05 Capitalization 9.09M 99.03M
Net income 2022 -20M -218M Net income 2023 -18M -196M EV / Sales 2022 119,226,800 x
Net cash position 2022 14.24M 155M Net cash position 2023 1.04M 11.37M EV / Sales 2023 1,608,986,800 x
P/E ratio 2022
-0.93 x
P/E ratio 2023
-0.41 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 4.17%
More Fundamentals * Assessed data
Dynamic Chart
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024. CI
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023 CI
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA MT
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023. CI
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA MT
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia CI
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Eurocine Vaccines Receives Patent Coverage In South Korea For Vaccine Candidate MT
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022 CI
More news
1 week-15.38%
Current month+227.38%
1 month+227.38%
3 months+89.66%
6 months-15.38%
Current year+19.57%
More quotes
1 week
0.04
Extreme 0.0422
0.07
1 month
0.01
Extreme 0.0146
0.11
Current year
0.01
Extreme 0.0146
0.11
1 year
0.01
Extreme 0.0146
1.39
3 years
0.01
Extreme 0.0146
7.38
5 years
0.01
Extreme 0.0146
27.40
10 years
0.01
Extreme 0.0146
1 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 03-12-31
Members of the board TitleAgeSince
Director/Board Member 86 11-12-31
Chief Executive Officer 66 03-12-31
Director/Board Member 64 03-12-31
More insiders
Date Price Change Volume
24-04-26 0.055 0.00% 4,334,662
24-04-25 0.055 -16.67% 3,632,114
24-04-24 0.066 +6.45% 1,396,510
24-04-23 0.062 +8.77% 14,663,845
24-04-22 0.057 -12.31% 8,105,001

End-of-day quote NORDIC GROWTH MARKET, April 25, 2024

More quotes
Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Company’s uses its clinically validated technology Endocine. In addition, the Company’s primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.
More about the company